Nadecnemab is an IGG4-kappaantibody targeting GFRA3, a receptor of the glial cell-derived neurotrophic factor family. Nadecnemab can be used for knee osteoarthritis and neurological disorders.
Target:
REGN-5069
* VAT and and shipping costs not included. Errors and price changes excepted
